Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Relapsed or Refractory PTCL
NCT02464228Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Feb 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tipifarnib in peripheral T-cell lymphoma (PTCL), sponsored by Kura Oncology. Started Feb 2016; status: completed.
02
Drugs
tipifarnib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02464228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464228.